What Is Duchenne Muscular Dystrophy And What Causes It?

Duchenne muscular dystrophy is a rare genetic disorder that causes progressive muscle weakness and loss. It is the most common and most severe form of muscular dystrophy, affecting mostly boys. The condition is caused by a mutation in the DMD gene, which is responsible for producing a protein called dystrophin. Without dystrophin, muscle cells become fragile and break down over time.

What Is Duchenne Muscular Dystrophy And What Causes It?

Duchenne muscular dystrophy (DMD) is a genetic condition that leads to progressive muscle degeneration. The disease is present from birth, but symptoms typically appear between ages 3 and 5. Most children with DMD are diagnosed by age 5, often after a parent or doctor notices delays in walking, frequent falls, or difficulty climbing stairs.

The cause is a mutation in the DMD gene on the X chromosome. This gene provides instructions for making dystrophin, a protein that acts like a shock absorber for muscle cells. When dystrophin is missing or severely defective, muscle fibers tear easily during normal use. The body tries to repair them, but over time the damage outpaces the repair. Muscle tissue is gradually replaced by scar tissue and fat.

Because the gene sits on the X chromosome, the condition follows a clear inheritance pattern. Males have one X and one Y chromosome, so a single faulty copy of the gene causes the disease. Females have two X chromosomes, so a mutation on one is usually masked by a healthy copy on the other. This is why DMD overwhelmingly affects boys. About one in 3,500 to 5,000 boys is born with the condition. In about one-third of cases, there is no family history — the mutation happens spontaneously.

What Are the First Signs and Symptoms?

The earliest signs of DMD often look like ordinary clumsiness or developmental delay. Children may walk on their toes, have a waddling gait, or need to use their hands to push themselves up from the floor. This last sign has a specific name: Gowers’ sign. A child with DMD will “walk” their hands up their thighs to stand because their leg muscles are too weak to push them up directly.

Other common early symptoms include:

• Delayed speech and language development
• Enlarged calf muscles, called pseudohypertrophy
• Difficulty running, jumping, or keeping up with peers
• Frequent falls
• Learning difficulties in about one-third of affected boys

Muscle weakness in DMD follows a predictable pattern. It starts in the hips, thighs, and shoulders before moving to the arms and legs. The heart and breathing muscles are also affected, but usually later in the disease course. Weakness is symmetrical — both sides of the body are affected equally.

How Is Duchenne Muscular Dystrophy Diagnosed?

Diagnosis begins with a blood test. Doctors measure a muscle enzyme called creatine kinase. In DMD, levels are extremely high because damaged muscle cells leak this enzyme into the bloodstream. Normal creatine kinase levels are typically below 200 U/L. In DMD, levels can be 50 to 100 times higher than normal.

An elevated creatine kinase level strongly suggests muscle damage but does not confirm DMD. The next step is genetic testing. A blood sample is analyzed to look for mutations in the DMD gene. Genetic testing confirms the diagnosis in about 95% of cases and has largely replaced muscle biopsy, which was the older standard method.

If genetic testing is inconclusive, a doctor may order a muscle biopsy. A small sample of muscle tissue is examined under a microscope. In DMD, the tissue shows absent or nearly absent dystrophin. The sample also reveals muscle fibers of varying sizes, areas of dead tissue, and replacement of muscle with fat and scar tissue.

How Does Duchenne Muscular Dystrophy Progress?

DMD follows a fairly predictable timeline, though the rate of progression varies from person to person. In early childhood, motor skills may actually appear normal or only mildly delayed. Between ages 3 and 7, weakness becomes more obvious. By age 7 to 12, most boys need a wheelchair. Loss of independent walking typically occurs around age 10 to 14 without treatment.

After the legs, weakness spreads to the arms and trunk. Contractures — permanent tightening of muscles and tendons — develop in the knees, hips, and elbows. Curvature of the spine, called scoliosis, is common and often requires surgical correction if the curve becomes severe.

In the teenage years, the heart and breathing muscles become involved. The heart muscle weakens, a condition called cardiomyopathy. Breathing muscles weaken, leading to poor cough and reduced lung capacity. These two complications — heart failure and respiratory failure — are the leading causes of death in DMD.

With modern care, many people with DMD live into their 30s and beyond. Older survival is increasingly common with aggressive cardiac and respiratory management. Without treatment, death usually occurs in the late teens or early 20s.

What Treatments Are Available?

There is no cure for DMD. But treatment has improved dramatically over the past two decades. The goal of treatment is to slow muscle damage, manage symptoms, and extend life. A multidisciplinary team — neurologist, cardiologist, pulmonologist, physical therapist, and others — provides the best care.

Corticosteroids are the mainstay of treatment. Prednisone and deflazacort have been shown to slow the decline in muscle strength and function. They also delay loss of walking by two to three years and reduce the need for spinal surgery. Steroids have significant side effects, including weight gain, bone thinning, growth delay, and behavioral changes. The decision to start steroids is made on an individual basis.

Physical therapy and stretching exercises help maintain joint flexibility and delay contractures. Standing frames and night splints are commonly used. Assistive devices — walkers, wheelchairs, and lifts — preserve independence as weakness progresses.

Cardiac care is essential. Boys are typically started on heart medications, such as ACE inhibitors or beta-blockers, in the early teen years even before symptoms appear. This proactive approach has been shown to delay heart failure. Breathing support, including non-invasive ventilation at night, is started when lung function declines. Immunizations against flu and pneumonia are strongly recommended.

Several targeted therapies have been approved in recent years. These include exon-skipping drugs, which are designed for specific mutations, and gene therapy, which aims to deliver a shortened but functional version of the dystrophin gene. These treatments are not cures, and their long-term benefits are still being studied. They are also only available to certain patients based on their specific genetic mutation.

Can Duchenne Muscular Dystrophy Be Prevented?

DMD cannot be prevented in a child who already has the mutation. However, families with a history of DMD can take steps before or during pregnancy. Genetic counseling helps families understand their risk. Carrier testing can identify women who carry a mutation in the DMD gene without showing symptoms themselves.

During pregnancy, prenatal testing can determine whether a fetus has DMD. This includes chorionic villus sampling, done around 10 to 12 weeks, and amniocentesis, done around 15 to 20 weeks. Preimplantation genetic diagnosis is another option. In this process, embryos created through in vitro fertilization are tested for the mutation before implantation.

These options are deeply personal and involve complex medical, ethical, and emotional decisions. Genetic counselors are trained to help families navigate these choices without bias.

What Is the Outlook for Someone With DMD?

The outlook for DMD has changed substantially. In the 1970s, most boys died in their late teens. Today, survival into the 30s is common, and some men live into their 40s. This improvement is due to better respiratory care, proactive cardiac management, and the widespread use of corticosteroids.

Quality of life is a major focus of current care. Advances in mobility devices, home ventilation, and cardiac support allow many men with DMD to complete education, pursue careers, and build relationships. Cognitive function is preserved in most cases, though learning disabilities and attention issues are more common than in the general population.

Research is active on multiple fronts. Gene therapy trials are ongoing, and newer exon-skipping drugs continue to be developed. While these treatments do not yet offer a cure, they represent meaningful progress in a disease that was once considered untreatable. Families should discuss realistic expectations with their care team, as access to new therapies depends on specific genetic mutations and current trial availability.